Traws Pharma Financials
This page shows Traws Pharma (TRAW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Traws Pharma has an operating margin of -62997.3%, meaning the company retains $-62997 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -8981.4% the prior year.
Traws Pharma's revenue grew a modest 0.0% year-over-year to $226K. This slow but positive growth earns a score of 33/100.
Traws Pharma's current ratio of 2.16 indicates adequate short-term liquidity, earning a score of 40/100. The company can meet its near-term obligations, though with limited headroom.
While Traws Pharma generated -$29.8M in operating cash flow, capex of $3.6M consumed most of it, leaving -$33.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Traws Pharma passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Traws Pharma generates $0.18 in operating cash flow (-$29.8M OCF vs -$166.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Traws Pharma generated $226K in revenue in fiscal year 2024. This represents an increase of 0.0% from the prior year.
Traws Pharma's EBITDA was -$142.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 601.9% from the prior year.
Traws Pharma reported -$166.5M in net income in fiscal year 2024. This represents a decrease of 778.8% from the prior year.
Traws Pharma earned $-35.21 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 56.0% from the prior year.
Cash & Balance Sheet
Traws Pharma generated -$33.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 86.3% from the prior year.
Traws Pharma held $21.3M in cash against $0 in long-term debt as of fiscal year 2024.
Traws Pharma had 4M shares outstanding in fiscal year 2024. This represents an increase of 334.5% from the prior year.
Margins & Returns
Traws Pharma's operating margin was -62997.3% in fiscal year 2024, reflecting core business profitability. This is down 54015.9 percentage points from the prior year.
Traws Pharma's net profit margin was -73682.7% in fiscal year 2024, showing the share of revenue converted to profit. This is down 65298.7 percentage points from the prior year.
Capital Allocation
Traws Pharma invested $12.8M in research and development in fiscal year 2024. This represents an increase of 12.4% from the prior year.
Traws Pharma invested $3.6M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 25957.1% from the prior year.
TRAW Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $2.7M+4694.7% | $57K+1.8% | $56K-1.8% | $57K0.0% | $57K+1.8% | $56K0.0% | $56K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.3M+0.9% | $2.3M-8.6% | $2.5M+34.9% | $1.9M-63.7% | $5.1M+29.0% | $4.0M+107.3% | $1.9M-21.4% | $2.4M |
| SG&A Expenses | $1.7M+3.1% | $1.7M-38.6% | $2.8M-20.8% | $3.5M-0.1% | $3.5M+76.0% | $2.0M-41.1% | $3.4M+61.0% | $2.1M |
| Operating Income | -$4.1M-224.7% | -$1.2M+76.0% | -$5.2M+1.4% | -$5.3M+38.2% | -$8.5M+93.1% | -$123.3M-2266.6% | -$5.2M-16.8% | -$4.5M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$4.0M-333.0% | -$915K-104.3% | $21.5M+171.8% | -$29.9M-253.1% | -$8.5M+93.1% | -$123.1M-2371.3% | -$5.0M-19.1% | -$4.2M |
| EPS (Diluted) | $-0.34-209.1% | $-0.11-105.3% | $2.09 | N/A | $-1.49 | $-20.52-246.6% | $-5.92 | N/A |
TRAW Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $12.4M-20.3% | $15.6M-18.1% | $19.1M-23.6% | $25.0M+179.3% | $8.9M-52.2% | $18.7M+2.8% | $18.2M-19.9% | $22.7M |
| Current Assets | $9.6M-37.4% | $15.4M-18.5% | $18.9M-24.4% | $25.0M+179.6% | $8.9M-52.2% | $18.7M+2.9% | $18.2M-19.9% | $22.7M |
| Cash & Equivalents | $6.4M-50.9% | $13.1M-17.9% | $15.9M-25.3% | $21.3M+294.4% | $5.4M-68.0% | $16.9M+3.0% | $16.4M-20.3% | $20.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $7.9M+7.3% | $7.4M-43.7% | $13.1M-76.9% | $56.6M+415.9% | $11.0M-91.2% | $124.2M+921.7% | $12.2M+1.2% | $12.0M |
| Current Liabilities | $7.9M+7.3% | $7.4M-29.3% | $10.4M-9.8% | $11.5M+38.2% | $8.3M-15.8% | $9.9M+5.2% | $9.4M+2.2% | $9.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $4.5M-45.0% | $8.3M+37.7% | $6.0M+119.0% | -$31.6M-1455.8% | -$2.0M+98.1% | -$105.5M-1854.3% | $6.0M-43.6% | $10.7M |
| Retained Earnings | -$632.5M-0.6% | -$628.6M-0.1% | -$627.7M+3.3% | -$649.2M-4.8% | -$619.2M-1.4% | -$610.8M-25.3% | -$487.6M-1.0% | -$482.6M |
TRAW Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.0M+32.9% | -$6.0M-10.0% | -$5.4M-34.6% | -$4.0M+64.8% | -$11.5M-16.5% | -$9.9M-122.7% | -$4.4M+0.1% | -$4.4M |
| Capital Expenditures | N/A | N/A | N/A | $0 | $0 | N/A | N/A | $0 |
| Free Cash Flow | N/A | N/A | N/A | -$4.0M+64.8% | -$11.5M | N/A | N/A | -$4.4M |
| Investing Cash Flow | N/A | N/A | N/A | $0 | $0 | N/A | N/A | $0 |
| Financing Cash Flow | -$62K-102.0% | $3.1M+23707.7% | $13K-99.9% | $20.0M | $0 | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TRAW Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | -45.7%+9082.4pp | -9128.1%+296.9pp | -9425.0%+5550.4pp | -14975.4%+201424.6pp | -216400.0%-207092.9pp | -9307.1%-1339.3pp | -7967.9% |
| Net Margin | N/A | -33.5%-37735.2pp | 37701.8%+91133.9pp | -53432.1%-38563.7pp | -14868.4%+201171.9pp | -216040.3%-207142.1pp | -8898.2%-1426.8pp | -7471.4% |
| Return on Equity | -87.2%-76.1pp | -11.1%-369.2pp | 358.2% | N/A | N/A | N/A | -82.8%-43.6pp | -39.2% |
| Return on Assets | -31.8%-26.0pp | -5.9%-118.6pp | 112.7%+232.6pp | -119.9%-25.0pp | -94.8%+564.2pp | -659.0%-631.6pp | -27.4%-9.0pp | -18.4% |
| Current Ratio | 1.22-0.9 | 2.09+0.3 | 1.81-0.4 | 2.16+1.1 | 1.07-0.8 | 1.88-0.0 | 1.93-0.5 | 2.46 |
| Debt-to-Equity | 1.74+0.8 | 0.89-1.3 | 2.18+4.0 | -1.79+3.6 | -5.40-4.2 | -1.18-3.2 | 2.02+0.9 | 1.13 |
| FCF Margin | N/A | N/A | N/A | -7214.3%+12919.0pp | -20133.3% | N/A | N/A | -7910.7% |
Note: Shareholder equity is negative (-$31.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Traws Pharma's annual revenue?
Traws Pharma (TRAW) reported $226K in total revenue for fiscal year 2024. This represents a 0.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Traws Pharma's revenue growing?
Traws Pharma (TRAW) revenue grew by 0% year-over-year, from $226K to $226K in fiscal year 2024.
Is Traws Pharma profitable?
No, Traws Pharma (TRAW) reported a net income of -$166.5M in fiscal year 2024, with a net profit margin of -73682.7%.
What is Traws Pharma's EBITDA?
Traws Pharma (TRAW) had EBITDA of -$142.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Traws Pharma's operating margin?
Traws Pharma (TRAW) had an operating margin of -62997.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Traws Pharma's net profit margin?
Traws Pharma (TRAW) had a net profit margin of -73682.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Traws Pharma's free cash flow?
Traws Pharma (TRAW) generated -$33.4M in free cash flow during fiscal year 2024. This represents a -86.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Traws Pharma's operating cash flow?
Traws Pharma (TRAW) generated -$29.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Traws Pharma's total assets?
Traws Pharma (TRAW) had $25.0M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Traws Pharma's capital expenditures?
Traws Pharma (TRAW) invested $3.6M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Traws Pharma spend on research and development?
Traws Pharma (TRAW) invested $12.8M in research and development during fiscal year 2024.
What is Traws Pharma's current ratio?
Traws Pharma (TRAW) had a current ratio of 2.16 as of fiscal year 2024, which is generally considered healthy.
What is Traws Pharma's debt-to-equity ratio?
Traws Pharma (TRAW) had a debt-to-equity ratio of -1.79 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Traws Pharma's return on assets (ROA)?
Traws Pharma (TRAW) had a return on assets of -667.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Traws Pharma's cash runway?
Based on fiscal year 2024 data, Traws Pharma (TRAW) had $21.3M in cash against an annual operating cash burn of $29.8M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Traws Pharma's debt-to-equity ratio negative or unusual?
Traws Pharma (TRAW) has negative shareholder equity of -$31.6M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Traws Pharma's Piotroski F-Score?
Traws Pharma (TRAW) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Traws Pharma's earnings high quality?
Traws Pharma (TRAW) has an earnings quality ratio of 0.18x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Traws Pharma?
Traws Pharma (TRAW) scores 18 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.